Physicians, researchers, and partner institutions across Europe aim to deliver innovative, personalized therapies more quickly Development project focused on a...
ALEXANDRIA, Va., Aug. 26, 2025 /PRNewswire/ -- BryceTech has secured three multi-year prime contracts from the U.S. Department of Defense,...
ALEXANDRIA, Va., Aug. 26, 2025 /PRNewswire/ -- BryceTech has secured three multi-year prime contracts from the U.S. Department of Defense,...
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone CAMBRIDGE, MA / ACCESS Newswire...
NEW CASTLE, Del., Aug. 21, 2025 /PRNewswire/ -- IgniteData, a leader in intelligent clinical trial data automation, is proud to announce...
CAMBRIDGE, MA / ACCESS Newswire / August 21, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced its participation in the following...
US Food and Drug Administration (FDA) has accepted the company's Type C meeting request and SKNJCT-003 Phase 2 study has...
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company...
SHELTON, CONNECTICUT / ACCESS Newswire / August 18, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"),...
First-in-human trial of Capricor’s StealthX™ vaccine initiated under HHS’s Project NextGenTrial conducted and funded by the National Institute of Allergy...
Saint Herblain (France), August 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced...
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business UpdatesEntered into a definitive...
AI Virtual Agents Powering Operational Gains for 135+ Healthcare Providers Through 1,000+ Distinct Flows SANTA BARBARA, Calif., Aug. 14, 2025...
STONY BROOK, NY / ACCESS Newswire / August 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the...
Favorable CDI-988 Phase 1 safety and tolerability reported Challenge study with CDI-988 as a norovirus preventive and treatment planned later this...
COPENHAGEN, Denmark, August 14, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered...
"Screen-Free Sleep" movement takes to the streets to address America's youth sleep crisis NEW YORK, Aug. 14, 2025 /PRNewswire/ --...
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical...
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical...
Apriori to leverage foundational insights from the Crick's Legacy Study to further validate Octavia™ platform's ability to predict viral evolution...